Absolute resonance strengths in the 6,7Li(alpha,gamma)10,11B reactions

The absolute strengths of the Ea=1175keV resonance in the 6Li(a,g)10B reaction and of the Ea=814 keV resonance in the 7Li(a,g)11B reaction have been measured to $\omega\gamma$=366+-38 meV and $\omega\gamma$=300+-32 meV, respectively, in good agreement with previous values. These resonances can be used to measure the absolute acceptance of the recoil separator ERNA to a precision of about 10%.Comment: 6 pages, 5 figures, to appear in European Physical Journal

A dimensioning and tolerancing methodology for concurrent engineering applications I: problem representation

This paper is the first of two which present a methodology for determining the dimensional specifications of all the component parts and sub-assemblies of a product according to their dimensional requirements. To achieve this goal, two major steps are followed, each of which is described in a paper. In the first paper, all relationships necessary for finding the values of dimensions and tolerances are represented in a matrix form, known as a Dimensional Requirements/Dimensions (DR/D) matrix. In the second paper, the values of individual dimensions and tolerances are determined by applying a comprehensive solution strategy to satisfy all the relationships represented in the DR/D matrix. The methodology is interactive and suitable for use in a concurrent engineering (CE) environment. The graphical tool presented in this paper will assist a CE team in visualizing the overall D&T problem and foreseeing the ramifications of decisions regarding the selection of dimensions and tolerances. This will assist the CE team to systematically determine all the controllable variables, such as dimensions, tolerances, and manufacturing processes

Restricted Coasean Bargaining

We investigate the efficiency of Coasean bargaining when restrictions are placed on the set of feasible bargaining outcomes. When property rights are costly to (defend) appropriate, we find bargaining restrictions may be Pareto superior to unconstrained voluntary exchange. Under cost uncertainty over the externality, we show an efficient configuration of restrictions must balance the potential reduction in appropriation costs with the possibility of allocatively inefficient bargaining restrictions. For cases where the restrictions are contested, we show conditions for the continuing existence of welfare improvements

Deciphering Genomic Alterations in Colorectal Cancer through Transcriptional Subtype-Based Network Analysis

<div><p>Both transcriptional subtype and signaling network analyses have proved useful in cancer genomics research. However, these two approaches are usually applied in isolation in existing studies. We reason that deciphering genomic alterations based on cancer transcriptional subtypes may help reveal subtype-specific driver networks and provide insights for the development of personalized therapeutic strategies. In this study, we defined transcriptional subtypes for colorectal cancer (CRC) and identified driver networks/pathways for each subtype. Applying consensus clustering to a patient cohort with 1173 samples identified three transcriptional subtypes, which were validated in an independent cohort with 485 samples. The three subtypes were characterized by different transcriptional programs related to normal adult colon, early colon embryonic development, and epithelial mesenchymal transition, respectively. They also showed statistically different clinical outcomes. For each subtype, we mapped somatic mutation and copy number variation data onto an integrated signaling network and identified subtype-specific driver networks using a random walk-based strategy. We found that genomic alterations in the Wnt signaling pathway were common among all three subtypes; however, unique combinations of pathway alterations including Wnt, VEGF and Notch drove distinct molecular and clinical phenotypes in different CRC subtypes. Our results provide a coherent and integrated picture of human CRC that links genomic alterations to molecular and clinical consequences, and which provides insights for the development of personalized therapeutic strategies for different CRC subtypes.</p></div

Schematic overview of methods used.

<p>(A) Study design. A detailed description of methods and data used in the study can be found in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0079282#pone.0079282.s001" target="_blank">Table S2 in File S1</a>; (B) Overview of the method used for inferring upstream driver subnetworks for individual subtypes.</p

Distinct mechanisms driving unique cancer biology and clinical outcome in different transcriptional subtypes.

<p>Note: **: FDR<0.01; *: 0.01</p

Kaplan-Meier plots of overall survival of patients from three CRC subtypes.

<p>Combining data from Moffit Cancer center, Vanderbilt Medical center and Max Planck Institute as a single cohort, we got 251 samples totally (left panel) and 161 samples from CRC stage II and III (right panel).</p